Manuscript

IMNN-101 Preclinical Data in SARS CoV-2 Published in Peer-Reviewed Journal Vaccine

Retrieved on: 
Thursday, February 22, 2024
SARS-CoV-2, Vaccine, FDA, Food, Manuscript, COVID-19, Drug discovery, Immunity, Elsevier, IND, DNA, Mouse

LAWRENCEVILLE, N.J., Feb. 22, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, announces that an article titled “Strong immunogenicity & protection in mice with PlaCCine: A COVID-19 DNA vaccine formulated with a functional polymer” by Subeena Sood, Majed M. Matar, et. Al. [https://doi.org.10.1016/j.vaccine.2024.01.065] has been published in the peer-reviewed journal Vaccine, by Elsevier. The article is available at https://authors.elsevier.com/sd/article/S0264-410X(24)00077-X.

Key Points: 
  • [ https://doi.org.10.1016/j.vaccine.2024.01.065 ] has been published in the peer-reviewed journal Vaccine, by Elsevier.
  • The study described in the article used IMUNON’s proprietary formulation against the spike proteins from two SARS-CoV-2 variants, both alone and in combination.
  • DNA formulated with PlaCCine resulted in a DNA vaccine product that was stable for up to one year at 4°C.
  • Dr. Corinne Le Goff, president and chief executive officer of IMUNON, said, “The publication of this manuscript in the prestigious peer-reviewed journal Vaccine adds to the growing body of preclinical data confirming the efficacy and desirable features of our PlaCCine vaccine modality.

ClearPoint Neuro Announces FDA Clearance and First-in-Human Cases Performed with the New 2.2 Software Version and the Integrated Maestro Brain Model

Retrieved on: 
Wednesday, February 21, 2024
NeuroImage, Spine, FreeSurfer, FDA, Biopsy, Paper, Surgeon, Manuscript, Deep brain stimulation, Brain, Medical device

“The Maestro Brain Model, and its integration into the recently FDA cleared ClearPoint 2.2 navigation software, is our latest example of just that.

Key Points: 
  • “The Maestro Brain Model, and its integration into the recently FDA cleared ClearPoint 2.2 navigation software, is our latest example of just that.
  • The ClearPoint system can now offer fast, peri-procedural segmentation of the cortical structures of the brain to identify both targets and safety zones for cell and gene therapy delivery, laser ablation, biopsy and deep brain stimulation.
  • This manuscript introduces the methodology for shape-constrained deformable brain segmentation behind Maestro, describes the validation performed for its FDA clearance, and presents a comparison with manual expert segmentation and FreeSurfer, an open-source segmentation software.
  • Reproducibility error of Maestro (green), FreeSurfer 7.2 (blue) and manual segmentation (red) for common brain structures (left), and average over all structures (right).

University of Phoenix College of Doctoral Studies Issues Call for Manuscripts in Upcoming Edition of Phoenix Scholar™ Academic Periodical

Retrieved on: 
Friday, March 8, 2024
Education, Other Education, University, College, AI, APA, Asian literature, Manuscript, Learning, Library, Faculty, ISSN, University of Phoenix, Doctor, Congress, Educational technology, Workforce, Publication, Artificial intelligence, Research, Evidence-based practice, Phoenix College, Student, Management

University of Phoenix College of Doctoral Studies invites submissions for a special issue on the burgeoning realm of Artificial Intelligence (AI) in its planned spring edition of Phoenix Scholar™ academic research periodical.

Key Points: 
  • University of Phoenix College of Doctoral Studies invites submissions for a special issue on the burgeoning realm of Artificial Intelligence (AI) in its planned spring edition of Phoenix Scholar™ academic research periodical.
  • The periodical, launched in 2017, highlights the commitment of University of Phoenix faculty, students and alumni to leading research through evidence-based practice.
  • “In an era marked by unprecedented technological advancements, AI stands as a transformative force with profound implications across various sectors, including academia,” shares Hinrich Eylers, Ph.D., P.E., vice provost, College of Doctoral Studies.
  • While the Phoenix Scholar does not publish original research studies, the editorial team invites submissions that celebrate recent publications or upcoming conference presentations related to AI.

BostonGene Announces Publication in Collaboration with National Cancer Institute and National Institute of Allergy and Infectious Diseases in Cancer Cell

Retrieved on: 
Thursday, March 7, 2024
Research, Infectious Diseases, Genetics, Clinical Trials, Health Technology, Biotechnology, Health, Science, Oncology, Other Science, Infection, Architecture, Bangladesh Technical Education Board, Follicular lymphoma, MD, Escape Room, Extracellular matrix, Manuscript, Apoptosis, National Cancer Institute, Lymph, Myelocyte, Malignancy, Death, ZIA, Tumor microenvironment, Medicine, Patient, Survival, Lymphoma, B cell, Vaccine

Throughout its progression, FL tumor B cells undergo significant genetic changes and extensively remodel the lymphoid microenvironment to promote survival and immune evasion.

Key Points: 
  • Throughout its progression, FL tumor B cells undergo significant genetic changes and extensively remodel the lymphoid microenvironment to promote survival and immune evasion.
  • Despite the urgent need, current clinical tools inadequately predict disease behavior, underscoring the necessity for risk stratification methods, particularly for early relapsers.
  • The study, led by researchers at the National Institute of Allergy and Infectious Diseases and National Cancer Institute in collaboration with BostonGene, employed a multi-modal approach to comprehensively examine cell-intrinsic and -extrinsic factors governing disease progression and therapeutic outcomes in FL patients enrolled in a prospective clinical trial.
  • The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

LRS Reports Unmatched Cooling Power in Stroke Patients - Results of SISCO Clinical Study Presented at 2024 ISC

Retrieved on: 
Tuesday, March 5, 2024
Research, Medical Devices, Neurology, Hospitals, Clinical Trials, Cardiology, Managed Care, Health, Science, TSS, Temperature, FDA, Food, ISC, IDE, Stroke, Manuscript, Conference, MRS, Safety, Patient, LRS, Pharmaceutical industry

On February 7, 2024, at this year’s International Stroke Conference (ISC), Life Recovery Systems (LRS) presented the results of its IDE-approved SISCO Study , in which ischemic stroke patients were rapidly cooled with the ThermoSuit System (TSS).

Key Points: 
  • On February 7, 2024, at this year’s International Stroke Conference (ISC), Life Recovery Systems (LRS) presented the results of its IDE-approved SISCO Study , in which ischemic stroke patients were rapidly cooled with the ThermoSuit System (TSS).
  • The TSS cooled patients to 34°C in a record time of 40 minutes in this pilot study.
  • No previous stroke cooling studies have had such rapid cooling or any trend for outcome improvements in patients.
  • Matt Center, LRS CEO, notes, “This study demonstrates the unmatched cooling power and excellent safety of the ThermoSuit system, while showing a strong trend for improved outcomes.

TriSalus Life Sciences Announces Real-World Data Demonstrating the Ability of TriNav® to Successfully Treat Patients with Higher Disease Burden and to Improve Delivery of Therapeutics to Liver Tumors

Retrieved on: 
Thursday, February 29, 2024
Biotechnology, Pharmaceutical, Surgery, Oncology, Health, FDA, Medical Devices, Clinical Trials, Liver, FACS, Neoplasm, Blood, CMS, Immunotherapy, Liver disease, Hepatocellular carcinoma, Liver cancer, Manuscript, TACE, Data, Medicare, Patient, HCPCS, Disease, Clutch (eggs), HCC, Medical imaging

Key findings include that TriNav patients, despite a higher baseline disease burden and clinical complexity, showed overall clinical results comparable to patients with lower disease burden.

Key Points: 
  • Key findings include that TriNav patients, despite a higher baseline disease burden and clinical complexity, showed overall clinical results comparable to patients with lower disease burden.
  • In a matched cohort comparison, TriNav patients had fewer 30-day inpatient visits post-procedure than non-TriNav patients.
  • TriNav TARE patients with liver metastases had fewer clinical complications post-procedure vs. non-TriNav patients in a matched cohort comparison.
  • “This large sample size study underscores the particular benefits of the TriNav device compared to standard drug delivery systems.”

Clinical Review of Pegylated Interferons Suggests Formulation and Mechanism of Action May Improve Outcomes for MPN Patients

Retrieved on: 
Wednesday, February 21, 2024
Science, Biotechnology, Research, Pharmaceutical, Oncology, General Health, Health, Clinical Trials, Myeloproliferative neoplasm, PV, University of Alabama, PMF, News, Treatment, Polycythemia, Manuscript, Interferon, Safety, University, Contraindication, Primary myelofibrosis, Associate, Patient, MPN, Pharmaceutical industry

The manuscript, "Interferons in the Treatment of Myeloproliferative Neoplasms” was co-authored by 12 renowned myeloproliferative neoplasm (MPN) specialists and published in Therapeutic Advances in Hematology .

Key Points: 
  • The manuscript, "Interferons in the Treatment of Myeloproliferative Neoplasms” was co-authored by 12 renowned myeloproliferative neoplasm (MPN) specialists and published in Therapeutic Advances in Hematology .
  • Writing and editorial support were funded by PharmaEssentia, however authors retained full editorial control and provided final approval on all content.
  • “Interferons are immune modulators that have been used to treat MPNs for more than 35 years.
  • “This review will continue to help the greater medical community better understand the potential of interferons, as well as potential dosing regimens and combination therapies for patients,” said Albert Qin, M.D., Ph.D., Chief Medical Officer, PharmaEssentia.

Blue Earth Therapeutics Announces Publication of Results from Independent Clinical Experience with 177Lu-rhPSMA-10.1 in Treatment of Metastatic Castrate Resistant Prostate Cancer

Retrieved on: 
Tuesday, February 20, 2024
Science, Radiology, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Therapeutic index, DOI, Nuclear medicine, Prostate cancer, Neoplasm, Isotope, Teaching hospital, Physician, Safety, Food, PSMA, Treatment, Hope, Manuscript, Therapy, Patient, Optimism, Journal, PSA, Legislation, Prostate-specific antigen, Metastasis, Medical imaging

The manuscript, “First Safety and Efficacy Data with the Radiohybrid 177Lu-rhPSMA-10.1 for the Treatment of Metastatic Prostate Cancer,” has been published in the Journal of Nuclear Medicine (DOI https://doi.org/10.2967/jnumed.123.266741 ).

Key Points: 
  • The manuscript, “First Safety and Efficacy Data with the Radiohybrid 177Lu-rhPSMA-10.1 for the Treatment of Metastatic Prostate Cancer,” has been published in the Journal of Nuclear Medicine (DOI https://doi.org/10.2967/jnumed.123.266741 ).
  • In the 4 consecutive patients with metastatic prostate cancer who were evaluated, when looking at radiologic progression free survival (rPFS), 2 patients had not progressed at 24 and 18 months of follow-up.
  • 177Lu-rhPSMA-10.1 is an investigational radiohybrid (rh) Prostate-Specific Membrane Antigen-targeted radiopharmaceutical for the treatment of prostate cancer, and the lead candidate in Blue Earth Therapeutics’ development of next generation therapeutic radiopharmaceuticals.
  • “These promising clinical data give us further optimism in advancing 177Lu-rhPSMA forward in clinical development, with the hope to help treat patients with metastatic prostate cancer.

Healthy.io and Johns Hopkins Collaborate to Utilize New Patient-Facing Technology to Improve Wound Care Management

Retrieved on: 
Thursday, March 7, 2024
Diabetes, Caregiver, Telehealth, Vascular surgery, Manuscript, Communication, Risk, Amputation, Frontiers, Johns Hopkins, COVID-19, Prediabetes, Patient, Privacy, DFU, CDC, Research, Johns Hopkins Hospital, Wound healing, Nursing

BOSTON, March 7, 2024 /PRNewswire/ -- Healthy.io, the global leader in transforming the smartphone camera into a medical device, is launching a groundbreaking program utilizing smartphone-based technology to improve wound care management for patients suffering from chronic diabetic wounds. This pilot program expands access to Healthy.io's Minuteful for Wound solution to patients in the division of Vascular Surgery and Endovascular Therapy department at the Johns Hopkins Hospital.

Key Points: 
  • This pilot program expands access to Healthy.io's Minuteful for Wound solution to patients in the division of Vascular Surgery and Endovascular Therapy department at the Johns Hopkins Hospital.
  • Diabetes and chronic wounds are often connected, with 19-33% of patients with diabetes developing diabetic foot ulcers (DFU) or other chronic wound conditions in their lifetime.
  • Despite health systems' enthusiasm for telemedicine after the COVID-19 pandemic, research documenting the impact of patient-centered technologies on wound care is scarce.
  • "We are thrilled to be collaborating with Johns Hopkins to utilize this innovative technology, which empowers patients and their caregivers to take an active role in their wound care management," said Geoff Martin, CEO of Healthy.io.

Lab Community "Extremely Concerned" About Patient Access to Testing If FDA Regulates Lab-Developed Tests

Retrieved on: 
Tuesday, March 5, 2024
Marie Cassidy, Doctor of Philosophy, ARUP, MD, Synovial joint, Physician, FDA, ARUP Laboratories, Culture, 2005 in television, Manuscript, LDT, Feedback, Safety, Health, MedRxiv, Patient, Congress, Laboratory, Public, Medical device

"If labs cannot afford to comply with the proposed regulations, they will have to discontinue essential tests, and that harms patients."

Key Points: 
  • "If labs cannot afford to comply with the proposed regulations, they will have to discontinue essential tests, and that harms patients."
  • To better understand how clinical laboratorians perceive the proposed rule, ARUP Laboratories conducted a survey of the clinical laboratory community.
  • Most respondents identified themselves as lab managers, lab supervisors, lab directors, lab employees, medical directors, pathologists, physicians, clinicians, or PhD scientists.
  • Over a hundred thousand clinical laboratorians dedicate their professional lives to ensuring high-quality testing and patient care every day in the U.S.